Dublin, April 21, 2025 (GLOBE NEWSWIRE) -- The "Therapeutic Nuclear Drug Market Report 2025" has been added to ResearchAndMarkets.com's offering.
This report provides an in-depth analysis of the therapeutic nuclear drug market, detailing its characteristics, size, and growth patterns, as well as segmentation and regional insights. It also explores the competitive landscape, market shares, trends, and strategies while analyzing historical and forecasted growth across various geographies.
The therapeutic nuclear drug market has witnessed significant growth, expanding from $1.94 billion in 2024 to $2.23 billion in 2025, reflecting a CAGR of 15.1%. This growth is driven by rising regulatory approvals, enhanced use of patient-specific data, improved dosimetry techniques, increased awareness of nuclear medicines, and heightened R&D investments. Further expansion is anticipated, with the market projected to reach $3.86 billion by 2029 at a CAGR of 14.7%. Factors fueling this period's growth include a shift towards personalized medicine, rising healthcare infrastructure demands, increasing geriatric population, diagnostic imaging advancements, and personalized care delivery.
Key trends expected to shape the market include nanoparticle-based delivery systems, radionuclide therapy advancements, hybrid imaging systems, radiopharmaceutical manufacturing developments, and integrating AI and machine learning. The prevalence of cancer significantly impacts market demand, with therapeutic nuclear drugs playing a critical role in cancer treatments. The WHO projects over 35 million new cancer cases by 2050, up 77% from 2022. Thus, the increasing incidence of cancer is a crucial driver for market growth.
Strategic partnerships are vital for market players, enhancing R&D capabilities and facilitating innovative treatments. For instance, DeepC and PAIRE's partnership aims to revolutionize nuclear medicine diagnostics through AI integration. Similarly, in May 2024, Telix Pharmaceuticals acquired QSAM Biosciences to enhance its therapeutic pipeline with Samarium-153-DOTMP, targeting bone metastases and osteosarcoma.
Prominent companies in this sector include Bayer AG, Novartis International AG, Siemens Healthineers AG, and Ipsen SA, among others. North America was the largest market region in 2023, with Asia-Pacific, Western Europe, and emerging markets also covered in the report. Countries featured include Australia, Brazil, China, France, Germany, India, and more.
Reasons to Purchase:
- Access a global perspective with insights covering 15 geographies.
- Evaluate the effects of key macroeconomic factors, including conflict, pandemics, inflation, interest rates, and political shifts.
- Develop strategies based on localized data and analyses.
- Identify potential investment opportunities in growth segments.
- Gain a competitive edge using forecast data and market-shaping trends.
- Understand customer preferences using up-to-date market shares.
- Benchmark performance relative to key industry competitors.
- Utilize reliable, high-quality data for both internal and external presentations.
- Receive continuous data updates, including a robust Excel dashboard for easy extraction and analysis.
Report Overview:
This report addresses vital questions about the largest and fastest-growing markets for therapeutic nuclear drugs. It examines market dynamics in relation to the overall economy and demographic trends, providing insights into the forces that will shape the market going forward.
The report details market characteristics, size, growth, segmentation, and competitive landscape. It also includes regional and country-specific breakdowns, offering a deep dive into historical data and forecasts by geography. Impact analyses of global events, such as the Russia-Ukraine war and COVID-19 pandemic, are integrated into the forecast considerations.
Scope of the Report:
- Markets Covered:
- By Type: Radium-223, Lutetium-177, Iodine-131, Other Types
- By Distribution Channel: Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Research Institutes
- By Application: Thyroid, Bone Metastasis, Lymphoma, Other Applications
- Subsegments:
- Radium-223: Prostate cancer applications, mechanism, dosage
- Lutetium-177: Neuroendocrine tumor treatments, protocols, combination therapies
- Iodine-131: Thyroid cancer treatments, dosage, safety
- Other Types: Additional isotopes, emerging therapies, R&D trends
Key Companies Profiled: Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen SA, and Jubilant DraxImage Inc.
Geographic Coverage: The report covers major economies including Australia, Brazil, China, and more, spanning regions like Asia-Pacific, Western and Eastern Europe, North and South America, the Middle East, and Africa.
Data is presented in comprehensive formats, including PDF, Word, and an Excel dashboard, with analysis supported by end notes.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2025-2029 |
| Estimated Market Value (USD) in 2025 | $2.23 Billion |
| Forecasted Market Value (USD) by 2029 | $3.86 Billion |
| Compound Annual Growth Rate | 14.7% |
| Regions Covered | Global |
The companies featured in this Therapeutic Nuclear Drug market report include:
- Bayer AG
- Novartis International AG
- Siemens Healthineers AG
- Ipsen SA
- Jubilant DraxImage Inc.
- Mallinckrodt Pharmaceuticals PLC
- The Bracco Group
- Lantheus Medical Imaging Inc.
- Piramal Group
- Curium Pharmaceuticals
- Yantai Dongcheng Pharmaceutical Group Co. Ltd.
- Eckert & Ziegler
- Telix Pharmaceuticals Limited
- International Isotopes inc.
- Orano SA
- Q BioMed Inc.
- Molecular Targeting Technologies Inc
- Medi-Radiopharma Co. Ltd.
- Actinium Pharmaceuticals
- Fusion Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/5cgb1t
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
